Canopy Growth stock tumbles after announcing $200 million share sale plan
Investing.com - TD Cowen has lowered its price target on Twist Bioscience (NASDAQ:TWST) to $36.00 from $58.00 while maintaining a Buy rating on the stock. The company’s shares, which have declined 7.8% in the past week, are currently trading near their 52-week low of $27.12. According to InvestingPro analysis, the stock appears undervalued at current levels.
The firm cited Twist Bioscience’s narrowed fiscal year 2025 guidance, which now accounts for a step-down in Next-Generation Sequencing (NGS) revenue as a key customer transitions from clinical to commercial stage. Despite near-term challenges, InvestingPro data shows the company maintaining strong revenue growth of 25.3% over the last twelve months. Get access to 8 more exclusive InvestingPro Tips and comprehensive analysis in the Pro Research Report.
Despite the price target reduction, TD Cowen noted Twist delivered solid gross margin performance, beating estimates by 370 basis points, primarily driven by NGS outperformance.
The research firm reported that Twist’s synthetic biology (SynBio) revenues were lighter than expected in the fiscal third quarter, though still showing 20% year-over-year growth.
TD Cowen identified NGS as a key growth driver for Twist Bioscience through 2026, with minimal residual disease (MRD) applications expected to more significantly contribute to the company’s growth in the future.
In other recent news, Twist Bioscience reported a notable 18% increase in revenue for Q3 2025, reaching $96.1 million. Despite this growth, the company recorded an adjusted EBITDA loss of $8 million, though this marks an improvement from the previous fiscal year. In a related development, Evercore ISI adjusted its price target for Twist Bioscience from $50.00 to $46.00, maintaining an Outperform rating. The research firm cited strong performance in the next-generation sequencing segment and solid gross margins as positive indicators. These updates reflect recent developments surrounding Twist Bioscience.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.